Possible association between diabetes and bisphosphonaterelated jaw osteonecrosis. Medicationrelated osteonecrosis of the jaw wikipedia. Bisphosphonaterelated osteonecrosis of the jaws rev bras reumatol 2011. The present study retrospectively evaluated the clinical characteristics and evolution of bronj cases that were diagnosed and treated at a dental school from 2004 to 2011. Bisphosphonate related osteonecrosis of the jaws bronj.
Atypical femoral fractures afs and osteonecrosis of the jaw onj are wellknown adverse drug reactions adrs associated with bisphosphonates. Circulating microrna panel as a novel biomarker to. Medication related osteonecrosis of the jaws is a rare side effect of certain drugs. Bisphosphonates related osteonecrosis of the jaw bronj is related to the development of avascular osteonecrosis or osteochemonecrosis 1, 2. Bisphosphonates bp are pyrophosphate analogues, which share a common phosphorouscarbonphosphorous chemical core. Bisphosphonaterelated osteonecrosis of the jaws request pdf. In 2002, the food and drug administration fda received first reports related to several patients with cancer, treated with the iv bisphosphonates bp, who developed osteonecrosis of the jaw.
The pathogenesis of bisphosphonaterelated osteonecrosis of the jaw. Possible association between diabetes and bisphosphonate related jaw osteonecrosis. January 2003 to april 2017 and indexed in the medline national library of. During this time, bisphosphonate related osteonecrosis of the jaws bronj in human patients has been identified. It has been more than a decade since the first cases of osteonecrosis of the jaws were. The aetiology of bronj remains unknown, and the pathogenesis seems multifactorial and related to several local or general factors. Bisphosphonaterelated osteonecrosis of the jaws oxford. Bisphosphonate related osteonecrosis of the jaws bronj is among the most serious ones. Treatment of bronj remains controversial, as efficiency of medical and surgical approaches as well as a combination of these methods with supportive treatments have not been. Medication related osteonecrosis of the jaw mronj, which was first described in 2002, is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous highpotency bisphosphonates and denosumab, which decrease the risk of skeletal related events in patients with cancer and metastatic bone disease.
Only recently was a dog model for bronj developed for human oral surgery and medicine. The american society for bone and mineral research defines bronj as an area of exposed bone in the maxillofacial region that has not healed within 8 weeks after identification by a healthcare. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in australia. Endodontic implications of bisphosphonateassociated. Imaging findings in bisphosphonaterelated osteonecrosis. The underlying etiology is unclear and may be multifactorial. Bisphosphonates bps have been used for the management of bone metabolic diseases. Prevention of osteonecrosis of the jaw onj in patients on. Oral and intravenous bisphosphonate induced osteonecrosis of.
These compounds have been synthesised, and used in industry since the 19th century but it is only in the 1960s that their invitro ability to inhibit the precipitation of calcium phosphate was applied clinically. Bisphosphonate related osteonecrosis of the jaws bronj in osteoporotic males yong. Pdf therapy for bisphosphonaterelated osteonecrosis of the jaw. Several several risk factors for bronj have been identified, including type and cumulative dose of nbp, tooth extraction, and use of dentures. Oral and intravenous bisphosphonate induced osteonecrosis. Position paper on bisphosphonaterelated osteonecrosis of the jaw.
From the molecular viewpoint, bps are postulated to modulate the function of osteoclasts, reacting with a surface receptor or with an intracellular enzyme. Jan 04, 2012 bisphosphonate related osteonecrosis of the jaws. Medicationrelated osteonecrosis of the jaw mronj, which was first described in 2002, is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous highpotency bisphosphonates and denosumab, which decrease the risk of skeletalrelated events in patients with cancer and metastatic bone disease. As a rheumatologist who has seen and managed bisphosphonate related osteonecrosis of the jaws fung e, medwatch case reports. Prevention of osteonecrosis of the jaw onj in patients on bisphosphonate therapies summary this document provides a consensus based guideline, drawing on current documented best practices, for the undertaking of invasive dentaloral surgical procedures on patients taking bisphosphonate agents so as to minimise the risk, or prevent the. Bisphosphonaterelated osteonecrosis of the jaws bronj is among the most serious ones. Bronj bisphosphonaterelated osteonecrosis of jaws is a frequently encountered disease, particularly in the maxillofacial region, and a consequence of bisphosphonate use. The reported incidence of bronj is significantly higher with the iv preparations zoledronic acid and pamidronate while the risk appears to be minimal for.
Aetiopathogenesis of bisphosphonate related osteonecrosis of the jaw bronj chemically bisphosphonates have three important entity pcp backbone, r 1 and r 2 side chain. The site of occurrence of the osteonecrosis is the jaws, and presentation occurs more frequently in the mandible than in the maxilla. Identification of risk factors for bisphosphonateassociated. Hexapeptide libraries for enhanced protein ptm identification and relative. Osteonecrosis of jaws onj might be old, dating back a century in the form of phossy jaw. Study of the staging system in a series of clinical cases oral oncology, vol. Bisphosphonates and osteonecrosis of the jaws journal of. Bps show high binding capacity to the bone matrix, especially in sites of active bone metabolism.
Oral and intravenous bisphosphonate induced osteonecrosis of the jaws. A literature search of medline via pubmed and cochrane library. Tosi p, zamagni e, cangini d, tacchetti p, offidani m, ronconi s, et al. The purpose of this study was to compare surgical and nonsurgical approaches to the treatment of bronj and the possible usefulness of nd.
Underlying mechanisms and therapeutic strategies for bisphosphonate related osteonecrosis of the jaw bronj. Shortly after the turn of the century, a variety of case reports described a necrosis of the jaw bone in patients using bisphosphonates. Among cancer patients receiving highdose intravenous bisphosphonates, osteonecrosis of the jaw is dependent on dose and duration of therapy, 17 20 and has an estimated incidence of 1% to 12%. Bisphosphonaterelated osteonecrosis of the jaw onj is characterized by nonhealing exposed bone in the maxillofacial region in patients who have undergone bisphosphonate treatment. Bisphosphonates bp are drugs widely used in the treatment of diseases relating to bone. Oncology agents and medicationrelated osteonecrosis of the jaw. Oncology agents and medicationrelated osteonecrosis of. Oral bisphosphonate related osteonecrosis of jaws bronj.
With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have. Detailed pathologic studies are not yet available and, hence, one can only speculate on the pathogenic mechanisms. Chapter 16 discusses bisphosphonaterelated osteonecrosis of the jaws, and addresses that bisphosphonates are an important class of drugs in the management of bony metastases from solid tumours including breast and prostate cancer, the management of multiple myeloma, and the management of tumourrelated hypercalcaemia. How cancer patients can lower the risk of bisphosphonate. Pdf incidence and risk factors of bisphosphonaterelated. Bisphosphonate related osteonecrosis of the jaw onj is characterized by nonhealing exposed bone in the maxillofacial region in patients who have undergone bisphosphonate treatment. Drug related risk factors a bisphosphonate potency. Much attention has been given to the development of osteonecrosis of the jaws, concomitant with a history of bisphosphonate usage, particularly regarding inciting dental procedures. In a pressure chamber, the patient inhales pure oxygen through a mask or a head tent. To identify risk factors for bisphosphonaterelated onj and af. Bodem jp, kargus s, eckstein s, saure d, engel m, hoffmann j.
The literature is replete with evidence of a new complication associated with the use of bisphosphonates defined as avascular osteonecrosis of the jaw. Pcp back bone is responsible for the strong affinity of the bps for binding to hydroxyapatite hap and allows for a number of variations in structure based on substitution in the r 1 and r 2 positions on the. Several several risk factors for bronj have been identified, including type and cumulative dose of nbp, tooth extraction, and use of dentures 4. Bisphosphonaterelated osteochemonecrosis of the jaws british. Currently, an exposed area of necrotic jaw bone present for at least eight weeks in patients using. Bisphosphonate related osteonecrosis of the jaws the. In this article, bisphosphonate associated osteonecrosis or bon will be the terms used to describe an osteonecrosis of the jaws secondary to bisphosphonate therapy. Incidence of bisphosphonaterelated osteonecrosis of the jaw in highrisk patients undergoing surgical tooth extraction.
Management of bisphosphonaterelated osteonecrosis of the. Bisphosphonates are important drugs that are increasingly prescribed to reduce the morbidity associated with osteoclastmediated bone diseases. Underlying mechanisms and therapeutic strategies for bisphosphonaterelated osteonecrosis of the jaw bronj. American association of oral and maxillofacial surgeons advisory task force on bisphosphonate related osteonecrosis of the jaws. The osteonecrosis of the jaws onj is an adverse side effect of long. Incidence of bisphosphonate related osteonecrosis of the jaw in highrisk patients undergoing surgical tooth extraction. The management of bisphosphonaterelated osteonecrosis of the jaws bronj is still controversial. History, etiology, prevention, and treatment, second edition robert e.
Bisphosphonaterelated osteonecrosis of the jaw, tooth. Although the use of bps is beneficial for cancer and skeletal diseases treatments, bp. May 16, 20 advisory task force on bisphosphonaterelated ostenonecrosis of the jaws and american association of oral and maxillofacial surgeons, american association of oral and maxillofacial surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws, journal of oral and maxillofacial surgery, vol. Oral bisphosphonate related osteonecrosis of the jaw. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. Pdf bisphosphonate associated osteonecrosis of the jaw.
Osteochemonecrosis of the jaws is now a wellknown complication of. Early surgical laserassisted management of bisphosphonate. The risk of bisphosphonaterelated osteonecrosis of the jaw in children. T1 imaging findings in bisphosphonaterelated osteonecrosis of jaws. Additional important issues related to bisphosphonateassociated onj include. Osteonecrosis of the jaws rheumatology oxford academic. Medicationrelated osteonecrosis of the jaws is a rare side effect of certain drugs. Diagnostic tissue sampling may exacerbate the process and is. Prevention of osteonecrosis of the jaw onj in patients. All are equal, but some are more equal than others. Management of bisphosphonate related osteonecrosis of the jaw.
Please know that bon is no better or worse a term than the others that have found their way into the literature, but it is the name adopted by the american dental association, 3 the. Bisphosphonaterelated osteonecrosis of the jaw associated with dental implants. Harper and fung1, i wish to comment and raise questions on the recent editorial by kahn2 and article by etminan, et al 3. Bronj is a disease entity which has only been described relatively recently, and its multi. Bisphosphonates bps are a class of drugs used to treat osteoporosis and malignant bone metastasis.
Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in australia. Prevention of bisphosphonaterelated osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acida prospective study over 6 years. Utility of hyperbaric oxygen in treatment of bisphosphonate related osteonecrosis of the jaws. Pdf bisphosphonate related osteonecrosis of the jaws. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. Utility of hyperbaric oxygen in treatment of bisphosphonaterelated osteonecrosis of the jaws. This phenomenon, first observed after infusion of potent, nitrogencontaining bps for treating multiple myeloma and cancers involving bone metastasis, was termed bisphosphonate related osteonecrosis of the jaws bronj marx, 2003, ruggiero et al. Periapical disease and bisphosphonates induce osteonecrosis. The reasons for the presentation of osteonecrosis in the jaws versus other parts of the skeleton are unknown at this time. Bisphosphonaterelated osteonecrosis of the jaws bronj is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate therapy. While osteonecrosis can be debilitating and frequently the outcome is stabilization rather than cure of the disorder, the benefits of bisphosphonates outweigh the risks. Bisphosphonaterelated osteonecrosis of the jaw rev bras reumatol 2012.
Since intravenous administration leads to a higher drug exposure than the oral route, osteonecrosis related to oral bisphosphonate therapy is less common than that of related to intravenous forms such as zolendronate which is also more potent than oral bisphosphonates. American association of oral and maxillofacial surgeons advisory task force on bisphosphonaterelated osteonecrosis of the jaws. Bisphosphonate related osteonecrosis of the jaws rev bras reumatol 2011. Bisphosphonaterelated osteonecrosis of the jaws bronj is a welldescribed clinical condition with consistent radiographic findings.
This condition was previously known as bisphosphonate related osteonecrosis of the jaw bon or bronj because osteonecrosis of the jaws correlating with bisphosphate treatment was frequently encountered, with its first incident occurring in 2003. During a preliminary histomorphometric study aimed at assessing the rate of bone remodeling in the jaws of patients with surgically resected bronj, we found a defect of bone. Therapy for bisphosphonaterelated osteonecrosis of the jaw. Management of bisphosphonaterelated osteonecrosis of the jaw. Figure 1 from underlying mechanisms and therapeutic. One hundred and twentyeight patients 33 males, 95 females. American society for bone and mineral research asbmr as an area of exposed. Bisphosphonate use has increased in veterinary medicine over the last decade. While osteonecrosis can be debilitating and frequently the outcome is stabilization rather than cure of the disorder, the benefits of bisphosphonates outweigh the risks 1.
The purpose of this study was to describe the clinical characteristics of bisphosphonate related oste. T he increasing recognition that use of bisphosphonates may be associated with osteonecrosis of the jaw onj led the leadership of the american society for bone and mineral research asbmr to appoint a task force to address a number of key questions related to this disorder. This phenomenon, first observed after infusion of potent, nitrogencontaining bps for treating multiple myeloma and cancers involving bone metastasis, was termed bisphosphonaterelated osteonecrosis of the jaws bronj marx, 2003, ruggiero et al. Diagnosis and management of osteonecrosis of the jaw. To identify risk factors for bisphosphonate related onj and af. Bisphosphonaterelated osteonecrosis of the jaws bronj is a poorly understood pathologic entity from the standpoints of its nomenclature, frequency, pathogenesis, and best method of treatment. Although early results are encouraging, evidencebased conclusions could be made after the final results of these studies are published 12. Periodontal disease, dental implants, extractions and. Bisphosphonaterelated osteonecrosis of the jaws article in journal of the american dental association 1939 85. To prevent these adrs and to aid in the search for pathogenic mechanisms, knowledge of risk factors can be helpful. Bisphosphonaterelated osteonecrosis of the jaw scielo. Circulating microrna panel as a novel biomarker to diagnose. Bronj bisphosphonate related osteonecrosis of jaws is a frequently encountered disease, particularly in the maxillofacial region, and a consequence of bisphosphonate use.
704 439 715 976 1251 241 1269 108 687 772 24 965 1106 267 1550 1435 743 954 1085 210 759 1432 584 889 1092 996 1477 1410 1052 1487 750 1068 273 1222